Clinical Trial: Antibody Phase I Study Targeting CD-352 for Relapsed/Refractory Myeloma Patients


A Phase I clinical trial testing an antibody that targets CD-352 is open for multiple myeloma patients who have had two lines of treatment including an immunomodulator and proteasome inhibitor. This study is in conjunction with Seattle Genetics and is open at 7 sites throughout the U.S.

To learn more, listen to Dr. Damian Green discuss this study:

Learn more about this clinical trial here:
CD-352 Clinical Trial


About Author

Jenny A

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

Leave A Reply

Please enter the correct captcha code to verify that you are human.